Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viatris Pipeline Progress Includes Eylea, Botox Biosimilars

Executive Summary

In its first sales and earnings call, Viatris management updated investors on the development of some key complex generics and biosimilars.

You may also be interested in...



Viatris Sets The Bar Low So There Will Eventually Be A Chance To Grow

Viatris' 2021 financial guidance was below investor expectations, suggesting a challenging road ahead for the newly formed company.

Biocon And Viatris Scoop EU Insulin Aspart Approval

Biocon and Viatris have landed their second biosimilar insulin approval in Europe, for a rival to Novo Nordisk’s NovoRapid (insulin aspart). Analyst reaction was lukewarm considering the “disappointing” launch of insulin glargine in Europe more than two years ago.

Mylan's Semglee Launch Marks US Multi-Source Competition To Lantus

Mylan is the first to launch insulin glargine competition in both a vial and pre-filled pen, joining Eli Lilly's Basaglar pen.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel